Mesenchymal stromal cell (MSC)–based therapies have emerged as a promising strategy for osteoarthritis (OA) treatment. In particular, infrapatellar fat pad (IPFP)–derived MSCs have become a good option to treat knee OA.
Purpose:
To investigate the influence of the local microenvironment of the knee joint, especially OA cartilage, on the bioactivities of injected/implanted IPFP MSCs.
Study Design:
Controlled laboratory study.
Methods:
Conditioned medium (CM) derived from OA cartilage fragments was collected and characterized. Donor-matched IPFP MSCs were treated with control medium (Dulbecco’s modified Eagle medium (DMEM)/F-12 or chondrogenic medium), control medium + CM, or CM alone; and a series of behaviors including the viability, migration, chondrogenic and hypertrophic differentiation, and catabolic activity of IPFP MSCs were evaluated among groups.
Results:
There were 14 cytokines detected in CM. CM treatment improved the viability of IPFP MSCs. CM hindered the migration of IPFP MSCs. In chondrogenic differentiation, the presence of CM increased the expression of chondrogenic markers but also enhanced the state of hypertrophy and catabolism.
Conclusion:
OA cartilage–secreted factors could induce chondrogenic differentiation but also resulted in negative effects including the weakened migration, increased hypertrophy, and catabolism of IPFP MSCs in vitro.
Clinical Relevance:
These findings provide an insight on the fate of IPFP MSCs after intra-articular injections.
Alves da SilvaMLCosta-PintoARMartinsA, et al. Conditioned medium as a strategy for human stem cells chondrogenic differentiation. J Tissue Eng Regen Med. 2015;9(6):714-723.
2.
AntonKBanerjeeDGlodJ. Macrophage-associated mesenchymal stem cells assume an activated, migratory, pro-inflammatory phenotype with increased IL-6 and CXCL10 secretion. PLoS One. 2012;7(4):e35036.
3.
AroraASriramMKothariAKattiDS. Co-culture of infrapatellar fat pad-derived mesenchymal stromal cells and articular chondrocytes in plasma clot for cartilage tissue engineering. Cytotherapy. 2017;19(7):881-894.
4.
AungAGuptaGMajidGVargheseS. Osteoarthritic chondrocyte-secreted morphogens induce chondrogenic differentiation of human mesenchymal stem cells. Arthritis Rheum. 2011;63(1):148-158.
5.
BiLKZhouNLiuC, et al. Kidney cancer cells secrete IL-8 to activate Akt and promote migration of mesenchymal stem cells. Urol Oncol. 2014;32(5):607-612.
6.
CoplandIBLord-DufourSCuerquisJ, et al. Improved autograft survival of mesenchymal stromal cells by plasminogen activator inhibitor 1 inhibition. Stem Cells. 2009;27(2):467-477.
7.
do AmaralRAlmeidaHVKellyDJO’BrienFJKearneyCJ. Infrapatellar fat pad stem cells: from developmental biology to cell therapy. Stem Cells Int. 2017;2017:6843727.
8.
DragooJLChangW. Arthroscopic harvest of adipose-derived mesenchymal stem cells from the infrapatellar fat pad. Am J Sports Med. 2017;45(13):3119-3127.
9.
DreierR. Hypertrophic differentiation of chondrocytes in osteoarthritis: the developmental aspect of degenerative joint disorders. Arthritis Res Ther. 2010;12(5):216.
10.
FahyNde Vries-van MelleMLLehmannJ, et al. Human osteoarthritic synovium impacts chondrogenic differentiation of mesenchymal stem cells via macrophage polarisation state. Osteoarthritis Cartilage. 2014;22(8):1167-1175.
11.
FischerJDickhutARickertM, et al. Human articular chondrocytes secrete parathyroid hormone-related protein and inhibit hypertrophy of mesenchymal stem cells in coculture during chondrogenesis. Arthritis Rheum. 2010;62(9):2696-2706.
12.
GoldringMBBerenbaumF. Emerging targets in osteoarthritis therapy. Curr Opin Pharmacol. 2015;22:51-63.
13.
HuangSSongXLiT, et al. Pellet coculture of osteoarthritic chondrocytes and infrapatellar fat pad-derived mesenchymal stem cells with chitosan/hyaluronic acid nanoparticles promotes chondrogenic differentiation. Stem Cell Res Ther. 2017;8(1):264.
14.
JoosHWildnerAHogrefeCReichelHBrennerRE. Interleukin-1 beta and tumor necrosis factor alpha inhibit migration activity of chondrogenic progenitor cells from non-fibrillated osteoarthritic cartilage. Arthritis Res Ther. 2013;15(5):R119.
15.
KhanWSAdesidaABTewSRAndrewJGHardinghamTE. The epitope characterisation and the osteogenic differentiation potential of human fat pad-derived stem cells is maintained with ageing in later life. Injury. 2009;40(2):150-157.
16.
KimYSChoiYJKohYG. Mesenchymal stem cell implantation in knee osteoarthritis: an assessment of the factors influencing clinical outcomes. Am J Sports Med. 2015;43(9):2293-2301.
17.
KimYSKohYG. Comparative matched-pair analysis of open-wedge high tibial osteotomy with versus without an injection of adipose-derived mesenchymal stem cells for varus knee osteoarthritis: clinical and second-look arthroscopic results. Am J Sports Med. 2018;46(11):2669-2677.
KohYGChoiYJKwonSKKimYSYeoJE. Clinical results and second-look arthroscopic findings after treatment with adipose-derived stem cells for knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2015;23(5):1308-1316.
20.
KohYGJoSBKwonOR, et al. Mesenchymal stem cell injections improve symptoms of knee osteoarthritis. Arthroscopy. 2013;29(4):748-755.
21.
KondoMYamaokaKSakataK, et al. Contribution of the interleukin-6/STAT-3 signaling pathway to chondrogenic differentiation of human mesenchymal stem cells. Arthritis Rheumatol. 2015;67(5):1250-1260.
22.
LaiJHRoganHKajiyamaG, et al. Interaction between osteoarthritic chondrocytes and adipose-derived stem cells is dependent on cell distribution in three-dimension and transforming growth factor-beta3 induction. Tissue Eng Part A. 2015;21(5-6):992-1002.
23.
LeijsMJvan BuulGMVerhaarJAHoogduijnMJBosPKvan OschGJ. Pre-treatment of human mesenchymal stem cells with inflammatory factors or hypoxia does not influence migration to osteoarthritic cartilage and synovium. Am J Sports Med. 2017;45(5):1151-1161.
24.
LiuYBuckleyCTAlmeidaHVMulhallKJKellyDJ. Infrapatellar fat pad-derived stem cells maintain their chondrogenic capacity in disease and can be used to engineer cartilaginous grafts of clinically relevant dimensions. Tissue Eng Part A. 2014;20(21-22):3050-3062.
25.
LopaSColombiniAMorettiMde GirolamoL. Injective mesenchymal stem cell-based treatments for knee osteoarthritis: from mechanisms of action to current clinical evidences. Knee Surg Sports Traumatol Arthrosc. 2019;27(6):2003-2020.
26.
LopaSColombiniASansoneVPreisFWMorettiM. Influence on chondrogenesis of human osteoarthritic chondrocytes in co-culture with donor-matched mesenchymal stem cells from infrapatellar fat pad and subcutaneous adipose tissue. Int J Immunopathol Pharmacol. 2013;26(1)(suppl):23-31.
27.
PasHIWintersMHaismaHJKoenisMJTolJLMoenMH. Stem cell injections in knee osteoarthritis: a systematic review of the literature. Br J Sports Med. 2017;51(15):1125-1133.
28.
PavonLFSibovTTde SouzaAV, et al. Tropism of mesenchymal stem cell toward CD133(+) stem cell of glioblastoma in vitro and promote tumor proliferation in vivo. Stem Cell Res Ther. 2018;9(1):310.
29.
PersYMRackwitzLFerreiraR, et al. Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase I dose-escalation trial. Stem Cells Transl Med. 2016;5(7):847-856.
30.
PricolaKLKuhnNZHaleem-SmithHSongYTuanRS. Interleukin-6 maintains bone marrow-derived mesenchymal stem cell stemness by an ERK1/2-dependent mechanism. J Cell Biochem. 2009;108(3):577-588.
31.
PuYWangMHongYWuYTangZ. Adiponectin promotes human jaw bone marrow mesenchymal stem cell chemotaxis via CXCL1 and CXCL8. J Cell Mol Med. 2017;21(7):1411-1419.
32.
RoosEMArdenNK. Strategies for the prevention of knee osteoarthritis. Nat Rev Rheumatol. 2016;12(2):92-101.
33.
SinghPMarcuKBGoldringMBOteroM. Phenotypic instability of chondrocytes in osteoarthritis: on a path to hypertrophy. Ann N Y Acad Sci. 2019;1442(1):17-34.
34.
SunYChenSPeiM. Comparative advantages of infrapatellar fat pad: an emerging stem cell source for regenerative medicine. Rheumatology (Oxford). 2018;57(12):2072-2086.
35.
van der KraanPMvan den BergWB. Chondrocyte hypertrophy and osteoarthritis: role in initiation and progression of cartilage degeneration?Osteoarthritis Cartilage. 2012;20(3):223-232.
36.
WaQLiuYHuangS, et al. miRNA-140 inhibits C3H10T1/2 mesenchymal stem cell proliferation by targeting CXCL12 during transforming growth factor-beta3-induced chondrogenic differentiation. Mol Med Rep. 2017;16(2):1389-1394.
37.
WallaceIJWorthingtonSFelsonDT, et al. Knee osteoarthritis has doubled in prevalence since the mid-20th century. Proc Natl Acad Sci U S A. 2017;114(35):9332-9336.
38.
XiaoweiCJiaMXiaoweiWYinaZ. Overexpression of CXCL12 chemokine up-regulates connexin and integrin expression in mesenchymal stem cells through PI3K/Akt pathway. Cell Commun Adhes. 2013;20(3-4):67-72.
39.
XieZTangSYeG, et al. Interleukin-6/interleukin-6 receptor complex promotes osteogenic differentiation of bone marrow-derived mesenchymal stem cells. Stem Cell Res Ther. 2018;9(1):13.
40.
XiongCJHuangBZhouY, et al. Macrophage migration inhibitory factor inhibits the migration of cartilage end plate-derived stem cells by reacting with CD74. PLoS One. 2012;7(8):e43984.
41.
XuFFZhuHLiXM, et al. Intercellular adhesion molecule-1 inhibits osteogenic differentiation of mesenchymal stem cells and impairs bio-scaffold-mediated bone regeneration in vivo. Tissue Eng Part A. 2014;20(19-20):2768-2782.
42.
YaoYDengQSongW, et al. MIF plays a key role in regulating tissue-specific chondro-osteogenic differentiation fate of human cartilage endplate stem cells under hypoxia. Stem Cell Rep. 2016;7(2):249-262.
43.
ZhangXXueKZhouJXuPHuangHLiuK. Chondrogenic differentiation of bone marrowderived stem cells cultured in the supernatant of elastic cartilage cells. Mol Med Rep. 2015;12(4):5355-5360.
